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in regard to public funding criteria. The following main types of restrictions were 
identiﬁ ed either because of the target public funding parameter affected or because of 
the reasoning: a) “because of lack of evidence”; b) “because it is the only effective 
treatment” (rule of rescue); c) “to improve efﬁ cacy”; d) “to improve efﬁ cacy-safety 
relation”; e) “to improve effectiveness”; f) “to improve cost-effectiveness”; and g) “to 
limit budget impact”. CONCLUSIONS: The limiting conditions should be perceived 
as tools to enable positive public funding decision when the current scope of ﬁ nancing 
is just behind the hypothetical threshold. Exploring and further analyzing methods 
and aspects concerning generating public funding restrictions is important for: 1) 
decision makers, so they be more aware of the consequences and impact of their 
decisions on the people/patients they serve, and could make more transparent deci-
sions; 2) HTA analysts, to focus their interest on the subsequent use of HTAs to help 
decision makers identify all potential options to rationally limit funding; 3) Market 
Access managers, so they used the identiﬁ ed mechanisms and methods to better foresee 
the public funding decisions concerning their drugs.
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OBJECTIVES: Since economic evaluation has been enforced to be considered for new 
drug reimbursement decisions in 2007, the structure and constituents of decision body, 
“Drug Reimbursement Evaluation Committee”, as well as the pharmacoeconomics 
report guideline promulgated by Health Insurance Review Assessment have been 
modiﬁ ed in Korea. These changes reﬂ ect deﬁ ciency in systematic adoption of economic 
evaluation and discontent among stakeholders. Recently, the fair and reasonable 
process and criteria have been highly emphasized at every level of policy administra-
tion in developed countries with concerns of increasing public demands for sustainable 
public practices and political acceptance of the importance of public accountability. 
Now, imminent practical task is how to connect the conceptual framework and fea-
sible practice for publicly accountable drug reimbursement decisions. METHODS: 
Using theoretical structure of public accountability published in the European Gover-
nance Paper, we analyzed qualiﬁ cations of drug reimbursement policy as ‘account-
ability’ and appraised the public accountability. We also performed interviews with 
ten key stakeholders from democratic, constitutional and learning perspectives. And 
then, recent reimbursement decision papers on two new drugs were analyzed to 
examine concrete shape of the accountability forums. RESULTS: Following scope of 
improvement would be suggested: (1) Clear and reasonable standards for coverage 
decision; (2) relevance of the standards to population’s health needs and health equity 
impacts; (3) disclosure of data used for decision, procedure and results to public; and 
(4) the procurement of due process of challenging decisions. CONCLUSIONS: Given 
value pluralism in democratic liberalism, it is matter of course that formal or proce-
dural justice is given prominence. Conclusively, an explicit discussion for formal cri-
teria and procedure is the essential component of the ongoing policy process. 
Accountable drug policy administration is impossible without accountable policy 
process which is impossible without transparent criteria for all decision stages.
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BACKGROUND: In Western jurisdictions, coverage with evidence development (CED) 
is seen as a promising scheme for linking coverage decisions on innovative health tech-
nologies with the generation of additional evidence. Nonetheless, the implementation of 
such CED schemes is not guaranteed to be successful, with issues arising around both 
evidence generation and (dis)continued coverage of technologies. OBJECTIVES: This 
qualitative study aims to explore the practical experiences with CED schemes for tech-
nology coverage. METHODS: Semi-structured interviews were conducted with key 
stakeholders involved in the decision making process about reimbursement of health 
technologies in Australia, Belgium, Ontario (Canada), France, Germany, Galicia (Spain), 
Sweden, UK and USA. The questionnaire for the interview was developed on the basis 
of comprehensive literature review and expert opinion, addressing issues related to the 
aim of CED, initial assessment/appraisal, evidence development, re-assessment/re-
appraisal and coverage for technologies. RESULTS: CED schemes vary widely in the 
evidence generation, time frame, the regulation and funding of research, and the involve-
ment of stakeholders in the CED process. This variation is caused by the structure and 
ﬁ nancing of health services delivery, the aim of CED, and the type of health technology. 
The CED process is often non-transparent, particularly relating to the selection of 
technologies and the re-assessment/re-appraisal for coverage (dis)continuation. (Dis)
continued coverage of technologies is often primarily driven by the pressures from 
patients, health professional and health institutions to provide access to innovative 
technologies or public opinion. CONCLUSIONS: The successful implementation of 
CED schemes requires: a) a transparent (analytic) framework for the selection of health 
technologies and the generation of additional evidence; b) a clear legal authority to regu-
late evidence generation, time frame and research budget; c) a structural involvement of 
stakeholders in the process of CED; and d) a priori clear end points for the re-assessment/
re-appraisal and technology coverage. 
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BACKGROUND: The Dutch reimbursement procedure for expensive hospital drugs 
requires the submission of a baseline cost-effectiveness analysis together with a 
research plan for the period of temporary reimbursement in order to estimate the 
real-life cost-effectiveness after 4 years. In this situation, a Value-of-Information (VOI) 
analysis might identify the critical parameters that need to be studied in such outcome 
study. OBJECTIVES: To identify when a VOI analysis alongside sensitivity analyses 
is warranted, and when such VOI analysis will not impact the decision making process. 
METHODS: We used a hypothetical Markov model with three groups of parameters: 
costs, utilities and transition probabilities. We studied different conﬁ gurations of input 
parameters, forcing the outcomes into different directions on the CE-plane. For each 
input conﬁ guration we performed a multivariate sensitivity analysis (MSA) and a 
probabilistic sensitivity analysis (PSA). In the MSA, sensitivity was measured as per-
centage change from baseline INMB. Additionally, we analyzed the expected value of 
perfect information (EVPI) and the expected value of partial perfect information 
(EVPPI). Analyses were done for a range of threshold ICERs. RESULTS: For each 
situation it was possible to predict the shape (but not the absolute value) of the EVPI 
curve based on the PSA ﬁ ndings. When the PSA plot covered both northern quadrants, 
MSA and EVPPI came to the same ranking of the groups of parameters. When the 
outcomes were in the northeast quadrant the ranking differed: MSA indicated costs 
as most important parameters, for EVPPI this was utilities. When outcomes where in 
the southwest quadrant, costs were most important in MSA and EVPPI. For both 
other quadrants, MSA and EVPPI were close to zero for all groups. CONCLUSIONS: 
Whether MSA and EVPPI come to a different priority setting for future research 
depends both on the threshold ICER and on the location of results on the 
CE-plane.
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OBJECTIVES: To identify stakeholder perceptions of sponsored clinical trials in a 
publically funded New Zealand hospital, and then to identify the similarities and 
differences in perceptions across these stakeholder groups. The stakeholders are: 1) 
participants involved in clinical trials; 2) management and the multidisciplinary team; 
3) the larger South Auckland community; 4) government and decision makers; and 5) 
the pharmaceutical industry. METHODS: We use purposive sampling to select repre-
sentatives of the stakeholder groups, which provides 109 respondents. We gather data 
using focus groups, in-depth interviews, telephone interviews and surveys. RESULTS: 
Many of the respondents represent more than one stakeholder group. While there is 
consensus across the stakeholders on some costs and beneﬁ ts such as developing safe 
medicines and collecting useful data there are marked differences in perceptions in 
other areas, such as those indicated below. Most stakeholders perceive the risk of 
adverse reactions as the greatest cost to trial participants but the participants them-
selves do not regard this as signiﬁ cant. Pharmaceutical representatives, management 
and the multidisciplinary team feel that gaining access to new medicines motivates 
people to participate in a trial. Trial participants feel that the support is more impor-
tant to them than the medication. Most researchers and staff believe trial involvement 
increases their job satisfaction, motivation, knowledge and skills while a few have 
concerns that sponsor control leads to the loss of their ﬂ exibility and independence 
Generally there is a perception that New Zealand based clinical trials assist in the 
process of obtaining registration and subsidization of new drugs in New Zealand. 
However, this perception may be erroneous as location of trials is apparently not 
considered in the drug registration process. CONCLUSIONS: We ﬁ nd that most 
stakeholders are satisﬁ ed with the conduct of clinical trials in New Zealand and they 
believe the beneﬁ ts outweigh the costs.
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OBJECTIVES: Recent development of Health Technology Assessment worldwide 
increased requirement for real world data (e,g, risk management plans, drugs utiliza-
tion). Primary non-interventional research (NIR) involving physicians able to enrol 
patients is a means to generate such data. One key challenge of NIRs is the capacity 
to reﬂ ect real life conditions by providing unbiased estimations of physicians’ behav-
iours and patients outcomes in large representative samples. Participation of physi-
cians is often an issue when conducting NIRs. Lack of understanding of scientiﬁ c value 
of NIRs, compared to clinical trials, is often assumed to be the major reason for 
reluctance to participate. Our objective was to better understand perception of, moti-
vation to participate in and expectation from participation in NIRs by physicians. 
